TORRENT PHARMACEUTICALS LTD. - 500420 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceeding of 51st AGM held on 23-07-2024.23-07-2024
23-07-2024
Q1FY25 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Pharmaceuticals company Torrent Pharmaceuticals announced Q1FY25 results: Revenue at Rs 2,859 crore grew by 10% Gross Margin: 75.7%, Op. EBITDA margin at 31.6%, Growth: 14% Net Profit after tax at Rs 457 crore, up by 21% Other expenses include one-off expenses of Rs 20 crore (in international business) Adjusted for such one-off expenses, the underlying Op. EBITDA is Rs 924 crore and Op. EBITDA margin at 32.3% Result PDF23-07-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation.23-07-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Outcome Of Board Meeting Dated 23-07-2024
Outcome of Board Meeting Dated 23-07-2024.23-07-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post Quarterly Financial Result Conference call with investors / analyst18-07-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Consider And Approve The Audited Financial Results On Standalone Basis And Unaudited Financial Results (With Limited Review) On Consolidated Basis Of The Company For The Quarter Ended On 30-Jun-24.
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2024 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Tuesday, 23-Jul-24, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on 30-Jun-24.05-07-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates03-07-2024
Torrent Pharma - Focus On Branded Generics, Profitability: HDFC Securities
Its two plants Dahej and Bileshwarpura (oral onco) received the U.S. FDA clearance, and it expects launch momentum to start from Q1 FY2503-07-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cuttings in connection with the 51st Annual General Meeting and E-Voting Procedure.01-07-2024